Scientists pinpoint protein that could improve small cell lung cancer therapies

(Virginia Commonwealth University) Approximately 15 percent of all lung cancers are small cell lung cancers, which grow rapidly and often develop resistance to chemotherapy. However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

The number of elderly people with advanced lung cancer is increasing globally owing to the aging population and advances in cancer therapy [1]. More than 50% of patients diagnosed with lung cancer are aged>65 years, which is the lower limit for defining “elderly” in epidemiologic researches [2]. Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both the elderly [3] and the adults. Although platinum-combination regimens including newer agents are the standard first-line chemotherapy for most patients with adva nced NSCLC, their use in elderly patients remains controversial [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Publication date: 1 December 2018Source: International Journal of Pharmaceutics, Volume 552, Issues 1–2Author(s): Tao Cui, Xiaohong Li, Yaqian Shu, Xianzhou Huang, Yan Wang, Wenli ZhangAbstractIn the present study, we have developed the robust nanoparticles (MGC-GNP/PTX), which are TAMs and tumor cells-dual recognizable, for targeting cancer therapy. Of great importance, the developed nano-platforms are glutathione (GSH)-activable, which means it remains structure intact under normal physiological condition and can be disrupted when exposed to certain concentration of GSH. As demonstrated by the drug release assay in...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 3 October 2018Source: Chemico-Biological InteractionsAuthor(s): Pan Jiang, Hai Xu, Chuyue Xu, Aochang Chen, Lijun Chen, Ming Zhou, Ijaz ul Haq, Xiaoyue Wu, Zahula Mariyam, Qing FengAbstractLong non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisi...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Abstract Long non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisition of cancer stem cell (CSC)-like properties. Cisplatin resistance remains a major obstacle in the treatment of lung cancer, and its mechanism is still not fully elucidated. Meanwhile, CSCs have been invo...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
New lung cancer therapies are constantly being developed and approved. Indeed, the new treatments on the market have rendered chemotherapy increasingly redundant. Matti Aapro, MD, of the Clinique de G... Author: VJOncology Added: 08/29/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Abstract BMI-1 (B-lymphoma Mo-MLV insertion region 1) is a key protein partner in polycomb repressive complex 1 (PRC1) that helps in maintaining the integrity of the complex. It is also a key player in ubiquitination of histone H2A which affects gene expression pattern involved in various cellular processes such as cell proliferation, growth, DNA repair, apoptosis and senescence. In many cancers, Overexpression of BMI1correlates with advanced stages of disease, aggressive clinicopathological behavior, poor prognosis resistance to radiation and chemotherapy. BMI1 is emerging as a key player in EMT, chemo-resistance...
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Conclusion: The approaches of this review are to highlight the recent management advances and contrast the differences of treatment practice between Western and Asian countries.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Palliation may be the goal of care for some patients with intra-thoracic lung cancer. Factors such as the extent of disease, comorbidities, performance status, or symptom burden, may indicate that patients are unsuitable for more aggressive approaches with a curative intent. A palliative treatment plan implies a focus on the effective relief and control of symptoms, while preserving both the quality and quantity of life. Therapeutic measures may include palliative radiotherapy, palliative chemotherapy, or other forms of systemic treatment. In addition, certain interventional procedures may be used to achieve symptom pallia...
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
The objectives of the current study were to synthesize and test the effectiveness of a nanotechnology-based strategy utilizing folic acid (FA)-conjugated liposomes that incorporate both celastrol (Cs) and irinotecan (Ir) for targeted breast cancer therapy. Our results revealed the successful preparation of Cs and Ir-loaded folate-targeted liposomes (Lipo/Cs/Ir-FA) with a small particle size (∼190 nm) and polydispersity index (∼0.10). The formulation exhibited higher drug release profiles for both Ir and Cs at pH 5.0 compared to those at physiological pH, favoring cancer cell-targeted release. Furthermore, in vitr...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Lung Cancer